Please login to the form below
Takeda wins UK approval for cancer drug
Takeda's bone cancer treatment Mepact has won the backing of the UK's National Institute for Health and Clinical Excellence
Takeda Pharmaceutical won the backing of the UK's National Institute for Health and Clinical Excellence (NICE) for its Mepact (mifamurtide) drug, for the treatment of high-grade resectable non-metastic osteosarcoma.
Mepact is approved for use with chemotherapy after surgery for bone cancers that have not spread. The approval is conditional on Takeda providing a price discount, which it has agreed to do, according to NICE.
The agency reversed a decision from 2010 in which it rejected the drug. The initial economic analysis may not have adequately captured the health-related quality of life from the drug, NICE said.
The terms of the discount have not been disclosed at Takeda's request.
Takeda acquired the rights to Mepact when it purchased IDM Pharma in May, 2009.
Share
Related Hub content
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
